ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor Meeting Abstract
| Authors: | Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; McLeroy, J. |
| Abstract Title: | ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A807 |
| End Page: | A808 |
| Language: | English |
| ACCESSION: | WOS:000919423400732 |
| DOI: | 10.1136/jitc-2022-SITC2022.0776 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 776 -- Source: Wos |
